Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article
Dilip Shanghvi on Sun-Ranbaxy Deal (interviewer asks stupid questions) -> Link
Why Ranbaxy acquisition is a game-changer for SUN
- Ranbaxy is currently a distressed asset with USFDA issues and the current sales is very low compared to its true potential due to the fda ban on many of its plants
- Ranbaxy sells in >100 markets in the world including many growing emerging markets. So SUN can cross-sell its products in these markets piggybacking on Ranbaxy already established sales/distribution channels
- Ranbaxy has pipeline of 40+ ANDA including high value FTF's like Nexium
- Ranbaxy even has branded products in the developed markets. SUN is good at capitalizing full sales potential for sole-competitor/low-competitor assets.
Ranbaxy's US Derma Products
We have a major focus in Dermatology with a presence across markets, including the US, India and Brazil. We have a robust franchise in the Corticosteroids, Anti-infectives and Anti-acne segments. Our current portfolio in the US caters to both prescription and consumer driven Over-the-Counter (OTC) markets, the major brands being Ultravate, Kenalog and Lac Hydrin. We have the global licensing rights to market Luliconazole (a novel Anti-fungal) in 16 markets, including India, Malaysia, Singapore and South Africa.Quote
Ranbaxty's Absorbica US sales were ~$60m.-> http://articles.economictimes.indiatimes.com/2013-11-26/news/44487256_1_ranbaxy-laboratories-absorica-usfda
Quote: Acne drug Absorica, a generic version of isotretinoin, has been gaining market share since its launch in December 2012. The drug has a total market size of $1 billion (at the price of Absorica), which is growing at almost 15% annually. Absorica's market share in October was 19% and analysts expect it to touch around 24% by the end of 2013-14, given Ranbaxy's 30-month exclusivity period.